Redeye states that reported Q3 numbers were somewhat better than we expected, with sales and earning...
TCECUR (”Koncernen”) levererade en Q3-rapport som överraskade positivt på översta raden, men där mar...
Sales SEK 17.7m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -1.
Q3 sales -5% vs ABGe, EBITA -36% on weak margins FY guidance unchanged, implying ~25% EBITA gowth in...
Redeye comments on Modelon's Q3 2023 report, which was in line on the ARR side while slightly lower ...
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 47% for the quarter...
Redeye comments on Maximum Entertainment ahead of its Q3-results (due 15 November) where we expect a...
Redeye embraces the strong sales growth in the quarter, and we emphasise the coming revenue growth d...
Group net sales were EUR 31.4m in Q3 (Refinitiv consensus EUR 34m) meanwhile Q3 adjusted EBITDA was ...
Redeye believes that the management is effectively executing on their strategic plan.
Redeye updates on G5 following the company’s Q3-results which came in lower than expected.
Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced...
Redeye comments on Lytix’ third results in 2023. In October, the first readout from the phase II tri...
Sales of SEK 62m, up 26% y-o-y, EBIT -4.9m (-25.8m) Circular Energy continues growth, production at ...
Sales of SEK 33.4m, up 50.3% y-o-y, adj. EBIT SEK -2.
Growth of 17.5% and strong adj. EBITA margin of 8.8% (4.
Q3 income 6% below our ABGSCe due to lower NCI... .
STENOCARE published on November 9th its Q3-report for 2023.
Redeye was hoping for a bit more, particularly in terms of top-line.
Redeye leaves a comment on today’s news that Einar Pontén is stepping down as the CEO of Lipum and t...
